NCT00635921View on ClinicalTrials.gov

Ziprasidone in the Treatment of Borderline Personality Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Borderline Personality Disorder
Interventions
DRUG

ziprasidone

Dose flexible from 40 to 200 mg/d during 12 weeks

DRUG

Placebo

flexible doses from 40 to 200 mg/d during 12 weeks

Trial Locations (1)

08025

Department of Psychiatry, Sta. Creu and St. Pau Hospital, Barcelona

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Ministry of Health, Spain

OTHER_GOV

collaborator

REM-TAP Network

UNKNOWN

collaborator

Pfizer

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT00635921 - Ziprasidone in the Treatment of Borderline Personality Disorder | Biotech Hunter | Biotech Hunter